Prelude Therapeutics Publishes Phase 1 Abstract for PRT3789 SMARCA2 Degrader at ESMO 2024

Prelude Therapeutics Inc

Abstract details first clinical data for PRT3789, a first-in-class IV SMARCA2 degrader in SMARCA4-mutated advanced solid tumors.
As of March 7, 2024, 40 patients enrolled across 6 dose levels (24-212 mg); no DLTs or study-drug-related SAEs reported.
Dose-dependent decreases in SMARCA2 levels observed; RECIST partial responses and tumor shrinkage noted in heavily pretreated NSCLC and esophageal cancer.
Company will host investor webcast on September 13, 2024 at 12:00 PM EST following oral presentation at ESMO Congress.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.